Global big pharmaceutical companies have overcome the stagnant growth amid the COVID-19 pandemic.As Newsmp tallied the semi-annual reports of major global big pharmaceuticals, it was found that most of the big pharma recorded double-digit growth.The company with the biggest growth was Pfizer, whose

The combined exports of the top five pharmaceutical companies exceeded 170 billion won in the second quarter.The proportion of exports to sales has returned to double digits from 8% level in the first quarter but has decreased slightly compared to the same period last year.According to a recent repo

Entecavir and Tenofovir markets, both of which shared the hepatitis B treatment market, left poor performance.In particular, the entecavir market showed poor performance in most of the top 10 drugs YoY, which have prescription sales of more than 500 million won in half a year.Baraclude (BMS)’s semi-

Since Eliquis (BMS) won the final lawsuit against its substance patent, there has been a change in the direct oral anticoagulant (DOAC) market.Eliquis rose to second place by overtaking Xarelto (Bayer), and its prescription sales increased significantly as generic drugs, which had been growing the s

Daewon Pharmaceutical’s Codaewon S recorded the highest number of prescriptions in the first half among new drugs in the outpatient prescription market.A total of 11 new drugs listed in the outpatient prescription market since the second half of last year have achieved more than 1 billion won in the

The cumulative exports of diagnostic reagents in the first half of the year increased by more than 20% YoY, and the surplus also rose 16%.According to the Korea Customs Service, the cumulative exports of diagnostic reagents (HS3822) in the first half of 2021 was $887.68 million, up 21.93% from the s

Brand-name drugs (original pharmaceutical products), biopharmaceuticals, and non-biopharmaceuticals were found to be relatively cheap in Korea compared to foreign countries.On the other hand, prices of generic drugs and non-brand drugs have been confirmed to be high in Korea.Non-brand drugs are term

The price index for analgesics is rising steeply.According to Statistics Korea, as of the end of June, the consumer price index (CPI) for analgesics (2015=100) was 131.29, up 2.51p from the ends of the first quarter (end of March), 3.06p from the end of last year, and 7.26p from the same period the

As non-face-to-face sales became common in the aftermath of COVID-19 last year, Japanese pharmaceutical companies’ entertainment and sales promotional expenses decreased significantly.The entertainment expenses of the eight Japanese pharmaceutical companies all dropped compared to 2019, reducing the

Japanese pharmaceutical companies are surpassing 200 billion won in annual sales despite the shock wave of COVID-19.According to the major Japanese pharmaceutical companies’ reports, Takeda in 2017, Eisai in 2019, and Daiichi Sankyo last year exceeded 200 billion won in annual sales.Prior to this, A

Monthly drug retail sales exceeded 2 trillion won for the first time in June, escaping negative growth for the first time this year.According to Statistics Korea, monthly retail sales of pharmaceutical products in June rose 1.9% year-on-year to 2.025 trillion won.Retail sales of pharmaceuticals cont

The chronic disease with the highest number of patients last year was hypertension.Furthermore, malignant neoplasm (malignant tumors such as carcinoma and sarcoma) cost the most for national health insurance among the chronic disease.According to the data released by the Health Insurance Review & As

The combinations of Clopidogrel and Aspirin, which each dreamed of becoming a blockbuster in the early stages of release, are still in a lull.Far from blockbuster, it seems like products with quarterly sales of 1 billion won are unlikely to remain, if the current trend continues.According to IQVIA,

Choline Alfoscerate products, which have been suffering from difficulties such as clinical re-evaluation due to their efficacy, maintained their growth despite the confusion. The market size of Choline Alfoscerate in 1Q was 75 billion won, up 4% YoY, according to IQVIA.Many of the medium-large produ

Exports of diagnostic reagents, which had been growing since the outbreak of the COVID-19 pandemic, fell for the second straight month.According to the data from the Korea Customs Service, monthly exports of diagnostic reagents plummeted 21.7% YoY to $147.3 million in May.Although the growth has slo

The focus of the HIV treatment market is shifting to the new generation, which has an advantage in long-term safety.While the sales of Biktarvy (Gilead Sciences), which relieved the burden of boosters, exceeded 10 billion won in the first quarter, Dovato (GSK), a combination drug, also entered 2 bil

Since the outbreak of the COVID-19 pandemic, the market for Celecoxib and Naproxen+PPI has continued to grow.According to IQVIA, the Celecoxib market grew more than 9% in the first quarter to reach 20 billion won, and the Naproxen+PPI combination drug market also expanded by 9% to over 7 billion won

Four anticancer drugs (Olaparib (Lynparza), O; Cediranib, C; Durvalumab (Imfinzi), D; Tremelimumab, T) from AstraZeneca are expected to give hope to patients with platinum-resistant recurrent ovarian cancer for whom do not have available treatments.At the 2021 ASCO Annual Meeting, Korean researchers

Imfinzi (Durvalumab, AstraZeneca) demonstrated a 5-year overall survival rate of 42.9% for patients with unresectable stage 3 non-small cell lung cancer (NSCLC).Imfinzi has become a new standard therapy in this field by lowering the risk of death through consolidation therapy for one year after conc

Zolgensma, a treatment for spinal muscular atrophy (SMA), which is said to be the most expensive drug in existence, is finally landing in Korea.Novartis’ rare disease gene therapy Zolgensma (Ingredient: Onasemnogeneabeparvovec) is an ultra-high priced drug that costs KRW 2.5 billion (about $2.12 mil